AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Citius Oncology Stock Soars 10% on LYMPHIR™ Launch Anticipation
Generated by AI AgentAinvest Pre-Market Radar
Tuesday, Jun 24, 2025 8:26 am ET1min read
Citius Oncology's stock surged 10% in pre-market trading on June 24, 2025, driven by anticipation of the commercial launch of its FDA-approved cancer drug, LYMPHIR™, in the second half of the year.
Citius Oncology is gearing up for the U.S. commercial launch of LYMPHIR™, an immunotherapy targeting lymphoma. The company estimates significant revenue from this launch, which is expected to bolster its market position and financial performance.
Citius Oncology's stock has seen volatility in recent weeks, with a notable drop of 16.35% on June 23, 2025. However, the upcoming commercial launch of LYMPHIR™ has provided a boost to investor confidence, leading to the recent pre-market surge.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Serve Robotics Surges 5.16% as Trump Admin Boosts Robotics Push, Eyes 10X Revenue by 2026
Dec.12 2025
New Pacific Metals (NPM) Soars 7.98% as Base Metals Market Anticipates Supply/Demand Shifts
Dec.12 2025
Gevo Inc. (GEVO) Surges 6.22% on $26M BioRecro Partnership to Expand Carbon Management Capabilities
Dec.12 2025
Sable Offshore Soars 5.82% as Private Placement and Policy Tailwinds Drive Pre-Market Rally
Dec.12 2025
Mastercard Inc. Surges 4.55% as Fintech Optimism and AI Expansion Drive Pre-Market Rally
Dec.12 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet